1. Purdue joining pharma’s top settlement list alongside Merck, GSK, and Pfizer — Biosimilars running into more roadblocks in the US — Big Pharma companies pay for exclusive access to UK genetic data — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

R&D made to look bad

Discussion in 'Bristol-Myers Squibb' started by anonymous, Jun 6, 2019 at 12:40 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    The message today was that existing R&D sucks ! Goodbye typical BMS way - welcome biotech pace
     
  2. anonymous

    anonymous Guest

    I agree that was the message. But if you want to change why would we bring in a Novartis guy? They're notorious for being even slower than us!
     
  3. anonymous

    anonymous Guest

    I am guessing the complete lack of hematology knowledge in the current leadership. I do hope that he does not bring the terrible Novartis culture.
     
  4. anonymous

    anonymous Guest

    Remember when Tom said he looked up CART on YouTube? That was a bad move.
     
  5. anonymous

    anonymous Guest

    Celgene is loaded with ex Novartis people and the Celgene culture has been on a steady slide downward for the past 4-5 years! By the looks of things this “new company” will be a Novartis South company! God save us all!!
     
  6. anonymous

    anonymous Guest

    Celgene is not at all what it used to be. Although BMS may be worse, your once revered acquisition brings only future products...hopefully
     
  7. anonymous

    anonymous Guest

    BMS should get rid of as many Celgene people as they can! A lot of entitled, arrogant overpaid babies that need to find a real job where they have to work and be help accountable !
     
  8. anonymous

    anonymous Guest

    You are correct! They’ll never be happy and will always have one foot out the door waiting for the next Celgene.
     
  9. anonymous

    anonymous Guest

    The foot soldiers at BMS are good ! The management seems to be trying to fix the RD organization and literally experimenting at cost of peoples career and lives. The result - all good ones have continued to leave BMS. This IMD concept is surely going to be wrapped up after 2 years just when everyone was getting used to this system. I hope Gioavnni gets impatient with operations not science
     
  10. anonymous

    anonymous Guest

    Celgene culture was great until about 2015 when they starting bringing in Novartis lawyers and Senior managers. Since then, bonus has gone down, work for work sake has gone up, and the culture has spoiled.
     
  11. anonymous

    anonymous Guest

    One of the most asinine things I've read here. Operations has continued to execute at a high level, adapting to the ever-changing direction of 227 - all comers, pdl1, tmb bullshit, etc. Pivoting, executing, getting and producing high quality data and everytime the science has been wrong. We know PDL1 will work just fine, get it approved and then try to identify areas where it will beat Keytruda. The science is a sailboat without a rudder.
     
  12. anonymous

    anonymous Guest

    Absokutrly agree. And with TL getting the boot it shows that GC is worried about the direction of the science.
     
  13. anonymous

    anonymous Guest

    good effing riddance to Tom Lynch!
     
  14. SRFDP

    SRFDP Guest

    And with CS at integration's helm no wonder GC is worried even more so, not!
     
  15. anonymous

    anonymous Guest

    Its going to be Celgene folks all across RD
     
  16. anonymous

    anonymous Guest

    It should be Celgene across the board.
     
  17. anonymous

    anonymous Guest

    we made ourselves look bad.
     
  18. anonymous

    anonymous Guest

    RD is constantly in a state of change. It is difficult to do research when the processes keep changing.
    We are wasting talent ! It really sucks. I hope HR is reading this and the feedback to GC ! He really needs to reflect on his decisions and apologize for the PRA partnership blunder
     
  19. anonymous

    anonymous Guest

    You think there will be significant layoffs on the BMS R&D side right off the bat this year when it comes to immuno? And how will it go down in terms of timeline?
     
  20. anonymous

    anonymous Guest

    We need better drugs to develop not better peoples. Fouad is incredible, I hope he is retained.